Scholars Central

Conference abstractPublished 18 Oct 2018

Transcriptomic biomarkers based approach for predicting the risk of heart failure development in postinfarction patients with the use of the ddPCR method

Authors: Beata Burzynska, Monika Gora, Karolina Maciak, Agata Maciejak, Edyta Kostarska-Srokosz, Wlodzimierz Gierlak, Miroslaw Dluzniewski, Marek Kuch, Michal Marchel, Grzegorz Opolski, Agnieszka Segiet, Marek Kiliszek

Polish Academy of Sciences, Poland Mazovia Brodno Hospital, Poland Medical University of Warsaw, Poland Military Institute of Medicine, Poland

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Cardiovascular diseases are the most important cause of mortality in developed countries. Despite continuous advances in diagnosis and treatment, heart failure (HF) remains a serious medical, social and economic problem. An acute myocardial infarction (AMI) is an event in coronary artery disease often leading to the development of heart failure. Classic risk factors of HF only partially explain why some patients suffer later from decompensation of the left ventricle, whereas others function quite well. Aim: The aim of our study was to identify distinct biomarkers that correlate with HF development. Methodology: We collected blood samples from AMI patients on admission (1st day of AMI). Clinical evaluation was performed after six months of AMI and patients were divided into HF (n=37), non-HF (n=26) and moderate-HF groups (n=119). Microarrays were used to analyze individual gene expression profiles of the patients. Seven differentially expressed transcripts that best discriminate between HF, non-HF and moderate-HF patients were selected. Microarray results were validated by the ddPCR method using blood RNA. Reference values were obtained for all transcripts and all groups of patients and the HF prognosis risk score was calculated. Results & Conclusion: The obtained results show that the identified gene expression changes at the early phase of AMI allow differentiating patients who developed HF from those who did not and that they may serve as a convenient tool contributing to the prognosis of heart failure.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Beata Burzynska”
  • BylineArticles whose byline prints “Monika Gora”
  • BylineArticles whose byline prints “Karolina Maciak”
  • BylineArticles whose byline prints “Agata Maciejak”
  • BylineArticles whose byline prints “Edyta Kostarska-Srokosz”
  • BylineArticles whose byline prints “Wlodzimierz Gierlak”
  • BylineArticles whose byline prints “Miroslaw Dluzniewski”
  • BylineArticles whose byline prints “Marek Kuch”